ATE361745T1 - Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen - Google Patents
Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungenInfo
- Publication number
- ATE361745T1 ATE361745T1 AT02714977T AT02714977T ATE361745T1 AT E361745 T1 ATE361745 T1 AT E361745T1 AT 02714977 T AT02714977 T AT 02714977T AT 02714977 T AT02714977 T AT 02714977T AT E361745 T1 ATE361745 T1 AT E361745T1
- Authority
- AT
- Austria
- Prior art keywords
- carbamat
- compounds
- preventing
- neurodegenerative disorders
- treating neurodegenerative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27168201P | 2001-02-27 | 2001-02-27 | |
| US10/081,764 US20020165273A1 (en) | 2001-02-27 | 2002-02-21 | Carbamate compounds for use in preventing or treating neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE361745T1 true ATE361745T1 (de) | 2007-06-15 |
Family
ID=26765943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02714977T ATE361745T1 (de) | 2001-02-27 | 2002-02-21 | Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20020165273A1 (de) |
| EP (1) | EP1383489B1 (de) |
| JP (1) | JP4276840B2 (de) |
| KR (1) | KR100910928B1 (de) |
| CN (1) | CN1235579C (de) |
| AR (1) | AR035756A1 (de) |
| AT (1) | ATE361745T1 (de) |
| BR (1) | BR0207645A (de) |
| CA (1) | CA2439295C (de) |
| CY (1) | CY1106753T1 (de) |
| CZ (1) | CZ301203B6 (de) |
| DE (1) | DE60220043T2 (de) |
| DK (1) | DK1383489T3 (de) |
| ES (1) | ES2284845T3 (de) |
| HK (2) | HK1060516A1 (de) |
| HU (1) | HUP0303264A3 (de) |
| IL (2) | IL157591A0 (de) |
| MX (1) | MXPA03007718A (de) |
| MY (1) | MY138156A (de) |
| NO (1) | NO20033798L (de) |
| NZ (1) | NZ527990A (de) |
| PL (1) | PL364680A1 (de) |
| PT (1) | PT1383489E (de) |
| RS (1) | RS51055B (de) |
| RU (1) | RU2300373C2 (de) |
| TW (1) | TWI312679B (de) |
| WO (1) | WO2002067925A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005033093A1 (en) * | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| RS51269B (sr) * | 2004-09-16 | 2010-12-31 | Janssen Pharmaceutica N.V. | Upotreba 2-fenil-1,2-etandiol-(di)karbamata za tretiranje epileptogeneze |
| KR20110049901A (ko) * | 2004-10-15 | 2011-05-12 | 얀센 파마슈티카 엔.브이. | 신경변성 질환 치료에 사용하는 카바메이트 화합물 |
| US20070021500A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods for neuroprotection |
| KR101199499B1 (ko) * | 2005-07-26 | 2012-11-09 | 얀센 파마슈티카 엔.브이. | 물질 관련 장애를 치료하는 방법 |
| EA200970355A1 (ru) * | 2006-10-06 | 2009-12-30 | Янссен Фармацевтика Нв | Новый кристалл (s)-(+)-2-(2-хлорфенил)-2-гидроксиэтилкарбамата |
| CN101568362A (zh) * | 2006-10-30 | 2009-10-28 | 詹森药业有限公司 | 治疗抑郁症的方法 |
| EP2089011A1 (de) * | 2006-10-31 | 2009-08-19 | Janssen Pharmaceutica N.V. | Behandlung pervasiver entwicklungsstörungen |
| CA2803825C (en) * | 2010-07-02 | 2015-12-29 | Bio-Pharm Solutions Co., Ltd. | Phenylcarbamate compound and muscle relaxant containing the same |
| US9018253B2 (en) | 2010-07-02 | 2015-04-28 | Bio-Pharm Solutions Co., Ltd. | Phenylcarbamate compound and muscle relaxant containing the same |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| US20130060024A1 (en) * | 2011-09-07 | 2013-03-07 | Satori Pharmaceuticals, Inc. | Compounds useful for treating neurodegenerative disorders |
| JP6298766B2 (ja) * | 2011-12-27 | 2018-03-20 | バイオ−ファーム ソリューションズ カンパニー リミテッド | てんかんの予防または治療に使用するためのフェニルカルバメート化合物 |
| KR101717872B1 (ko) * | 2013-03-12 | 2017-03-17 | (주)바이오팜솔루션즈 | 소아 간질 및 간질-관련 증후군의 예방 또는 치료용 페닐카바메이트 화합물 |
| JP6096329B2 (ja) * | 2013-03-12 | 2017-03-15 | バイオ−ファーム ソリューションズ カンパニー リミテッド | フェニルカルバメート化合物及び記憶損失−関連疾患の予防又は治療用組成物 |
| WO2017150903A1 (en) | 2016-02-29 | 2017-09-08 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compounds, processes for preparing them and their uses |
| US11147798B2 (en) | 2016-12-14 | 2021-10-19 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease |
| CA3112166A1 (en) * | 2018-09-21 | 2020-03-26 | Sk Biopharmaceuticals Co., Ltd. | Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder |
| WO2022045824A1 (en) * | 2020-08-31 | 2022-03-03 | Bio-Pharm Solutions Co., Ltd. | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease |
| CN116234798A (zh) | 2020-09-10 | 2023-06-06 | 生物药品解决方案有限公司 | 用于治疗或缓解精神疾病的氨基磺酸酯衍生物化合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3313692A (en) * | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
| US3278380A (en) * | 1962-02-06 | 1966-10-11 | Armour Pharma | Methods of calming employing diphenyl hydroxy carbamate compounds |
| US3265728A (en) * | 1962-07-18 | 1966-08-09 | Armour Pharma | Substituted phenethyl carbamates |
| US5474990A (en) * | 1989-10-20 | 1995-12-12 | Olney; John W. | Barbiturates as safening agents in conjunction with NMDA antagonists |
| US5492930A (en) * | 1994-04-25 | 1996-02-20 | Schering Corporation | Method and formulation for treating CNS disorders |
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| US5728728A (en) * | 1996-04-10 | 1998-03-17 | Kozachuk; Walter E. | Methods of providing neuroprotection |
| US6232434B1 (en) * | 1996-08-02 | 2001-05-15 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
| HUP0303342A3 (en) * | 2001-02-27 | 2012-07-30 | Ortho Mcneil Pharm Inc | Carbamate compounds for use in preventing and treating psychotic disorders |
| KR100946944B1 (ko) * | 2001-02-27 | 2010-03-15 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | 양극성 장애의 예방 또는 치료용 카바메이트 화합물 |
| CZ20032299A3 (cs) * | 2001-02-27 | 2004-08-18 | Ortho@Mcneilápharmaceuticalźáinc | Léčivo pro prevenci nebo léčbu motorických poruch |
-
2002
- 2002-02-21 RU RU2003128982/14A patent/RU2300373C2/ru not_active IP Right Cessation
- 2002-02-21 DE DE60220043T patent/DE60220043T2/de not_active Expired - Lifetime
- 2002-02-21 IL IL15759102A patent/IL157591A0/xx unknown
- 2002-02-21 AT AT02714977T patent/ATE361745T1/de active
- 2002-02-21 BR BR0207645-4A patent/BR0207645A/pt not_active Application Discontinuation
- 2002-02-21 JP JP2002567292A patent/JP4276840B2/ja not_active Expired - Fee Related
- 2002-02-21 CN CNB028087178A patent/CN1235579C/zh not_active Expired - Fee Related
- 2002-02-21 HU HU0303264A patent/HUP0303264A3/hu unknown
- 2002-02-21 PT PT02714977T patent/PT1383489E/pt unknown
- 2002-02-21 WO PCT/US2002/005541 patent/WO2002067925A1/en active IP Right Grant
- 2002-02-21 RS YUP-674/03A patent/RS51055B/sr unknown
- 2002-02-21 DK DK02714977T patent/DK1383489T3/da active
- 2002-02-21 EP EP02714977A patent/EP1383489B1/de not_active Expired - Lifetime
- 2002-02-21 CZ CZ20032313A patent/CZ301203B6/cs not_active IP Right Cessation
- 2002-02-21 NZ NZ527990A patent/NZ527990A/en unknown
- 2002-02-21 ES ES02714977T patent/ES2284845T3/es not_active Expired - Lifetime
- 2002-02-21 MX MXPA03007718A patent/MXPA03007718A/es active IP Right Grant
- 2002-02-21 KR KR1020037011302A patent/KR100910928B1/ko not_active IP Right Cessation
- 2002-02-21 US US10/081,764 patent/US20020165273A1/en not_active Abandoned
- 2002-02-21 CA CA2439295A patent/CA2439295C/en not_active Expired - Fee Related
- 2002-02-21 PL PL02364680A patent/PL364680A1/xx unknown
- 2002-02-27 TW TW091103504A patent/TWI312679B/zh active
- 2002-02-27 MY MYPI20020697A patent/MY138156A/en unknown
- 2002-02-27 AR ARP020100697A patent/AR035756A1/es unknown
-
2003
- 2003-08-26 IL IL157591A patent/IL157591A/en not_active IP Right Cessation
- 2003-08-26 NO NO20033798A patent/NO20033798L/no not_active Application Discontinuation
-
2004
- 2004-03-10 US US10/797,795 patent/US20040171679A1/en not_active Abandoned
- 2004-05-17 HK HK04103497A patent/HK1060516A1/xx not_active IP Right Cessation
- 2004-10-26 HK HK04108387A patent/HK1065486A1/xx not_active IP Right Cessation
-
2007
- 2007-07-24 CY CY20071100982T patent/CY1106753T1/el unknown
-
2008
- 2008-09-10 US US12/207,816 patent/US20090005442A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE361745T1 (de) | Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen | |
| DE60114580D1 (de) | Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen | |
| DE60102016D1 (de) | Verfahren zur behandlung von beweggungsstörungen | |
| ATE515261T1 (de) | Zusammensetzungen zur behandlung von diabetes | |
| DE60019158D1 (de) | Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien | |
| DE69925865D1 (de) | 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen | |
| ATE369130T1 (de) | Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen | |
| DE60233186D1 (de) | Verbessertes System zur Behandlung von Elementarschwefel-Rückständen | |
| DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
| DE60208221D1 (de) | Heterozyklische verbindungen zur behandlung von harnwegserkrankungen | |
| DE502004010131D1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
| ATE279386T1 (de) | Retinoide zur behandlung von emphysem | |
| DE60327074D1 (de) | Fluorobenzamide zur behandlung von alzheimer oder seniler dementia | |
| ATE493125T1 (de) | Carbamatverbindungen zur behandlung von schmerz | |
| DE60101309D1 (de) | Diacerein zur behandlung von psoriasis | |
| DE60223688D1 (de) | Verfahren zur behandlung von multiplem myelom | |
| DE69943089D1 (de) | Methode zur behandlung von staphylokokkeninfektionen | |
| DE602004019576D1 (de) | Zur behandlung von schmerzen geeignete piperazine | |
| DE69941821D1 (de) | Fluorenthaltende zusammensetzung zur behandlung von oberflächen | |
| DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis | |
| DE60223718D1 (de) | Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen | |
| DE60224650D1 (de) | Vorrichtung zur behandlung von vorhof-fibrillation | |
| ATE346597T1 (de) | Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten | |
| ATE390134T1 (de) | (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen | |
| DE69904849T2 (de) | 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1383489 Country of ref document: EP |